Silevertinib

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameSilevertinib
Drug Alias NameBDTX-1535
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCentral Nervous System DiseasesCarcinoma, Non-Small-Cell LungBrain Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlack Diamond Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBlack Diamond Therapeutics IncBarrow Neurological Institute
Inactive CompaniesN/A
Active IndicationsCentral Nervous System DiseasesCarcinoma, Non-Small-Cell LungBrain Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A